Daylong session gathered leaders from across the national healthcare innovation landscape The NEWDIGS Initiative at the Massachusetts Institute of Technology held a Paying for Cures Workshop on August 7, attended … Read More
NEWDIGS turns 10!
Letter from Dr Gigi Hirsch Executive Director, MIT Center for Biomedical Innovation and Director, NEWDIGS In 2009 an international working group of biomedical research and healthcare leaders gathered at MIT … Read More
Payer Perspectives Survey
A survey of 77 payers representing over 280 million lives, completed in April 2019, explored perspectives concerning financing challenges and management strategies associated with durable cell and gene therapies. Download … Read More
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Value in Health, June 2019Casey Quinn, Colin Young, Jonathan Thomas, and Mark Trusheim Cell and gene therapies promise durable clinical benefit from a single treatment course. High upfront reimbursement for … Read More
Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Value in Health, June 2019Jane F. Barlow, Mo Yang, and J. Russell Teagarden Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. … Read More
Pediatric Gene Therapy Launches
Gene therapy cures for hereditary genetic conditions are likely to reach the United States market in the coming decades. Several disease areas with potential cures are orphan conditions, which affect … Read More
Patient & Caregiver Themes Survey
Patients and caregivers are key stakeholders in the development of system-wide, implementable precision financing models for durable and curative therapies. Patient and caregiver challenges are generally assumed to be primarily … Read More
Preparing Patients and the Health System for Curative Therapies in the Pipeline
American Journal of Managed Care Curative therapies represent a conundrum for healthcare. On the one hand, there is the ability to cure patients of potentially life-threatening diseases or diseases that … Read More
MIT Releases New Policy and Practice Suggestions to Make Cures Accessible and Sustainable
Innovative Therapies Will Require Innovations in Financing and Regulations WASHINGTON, DC, February 12—Today, the MIT-based Financing and Reimbursement of Cures in the US (FoCUS) consortium released a series of large-scale … Read More
Precision Financing of Durable, Potentially Curative Therapies
Pharmaceutical Executive, January 27, 2019 Trusheim, Jane Barlow Russell Teagarden Mark Gene therapies and cellular treatments create multiple financial challenges for US healthcare payers beyond price. The work of the … Read More